UK CROs Collaborate To Offer Cohesive Drug Discovery Services
News Mar 18, 2015
XenoGesis is teaming up with a group of UK-based Contract Research Organisations (CROs) and heading to Denmark on the 25th March 2015 on a market visit supported by UKTI and hosted at the residence of the British Ambassador in Copenhagen.
The market visit entitled, “The Changing Face of Pharmaceutical Discovery and Development – A Collaborative CRO Approach” will provide an opportunity for life science research companies across the Nordik region to meet and discuss how collaborative outsourcing can overcome the key scientific challenges within R&D.
Aimed at R&D scientists, project leaders and resource managers, the meeting will consist of opening presentations reflecting on current trends in outsourcing worldwide with particular reference to Scandinavia with guest speaker Dr Daniel Greve from Leo Pharma. Dr Richard Weaver, Managing Director of XenoGesis will also speak on “The importance of CROs in the rapidly evolving R&D sector.”
Representatives from all CROs will give an overview of how their services are applied to problem solving within the R&D pipeline. Further discussion is then planned over lunch and coffee breaks.
“Attracting new business is essential to our success. By having this collaborative approach and offering a comprehensive range of drug discovery activities, we are confident in providing an attractive proposition to Nordik companies seeking support with their research projects,” commented Richard Weaver, Managing Director of XenoGesis. “Clients recognise the value of specialist expertise and appreciate the quality and turnaround speed that dedicated organsisations can provide.”
The companies attending complement each other in their drug discovery activities and product development. Aurelia BioScience covers compound screening to identify hit and lead molecules. Organic synthesis is covered by Charnwood Molecular. XenoGesis are specialists in drug metabolism and pharmacokinetics (DMPK) testing. Reach Separations provides the analytical and chromatographic expertise, particularly for chiral compounds. Molecular Profiles provides pharmaceutical development services and clinical trial manufacturing for small molecules and can work from early phase development to late stage clinical manufacture. Biopta addresses the issue of translational relevance, proving data from tailored fresh human tissue assay systems; interfacing with the other groups by testing novel molecules for efficacy, absorption or safety in healthy and diseased tissue.
“We have a strong understanding of each others capabilities and how we can work together effectively to become more competitive,” commented Peter Ridgway of Reach Separations. “As companies become more confident with outsourcing, the way they approach it is evolving. The need for a collaborative approach of bringing services together in this way is only going to grow.”
UKTI International Trade Adviser, Louise Stock, who has provided advice and support in arranging the market visit, added, “UKTI East Midlands is delighted to support the Nottingham based companies. The companies have been able to access funding from UKTI and we have further assisted them in identifying other sources of funding to support the market visit.”
The market visit follows a successful two-day visit to Switzerland last year organised and supported by UKTI.
Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant BacteriaNews
A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.READ MORE
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE